Advanced pulmonary fibrosis: Integrated management strategies.

Carlos Mendez*

Department of Pulmonary Diseases, University of Barcelona, Spain

Introduction

Idiopathic pulmonary fibrosis (IPF) remains a devastating progressive lung disease, leading to chronic respiratory failure. This updated review outlines current anti-fibrotic treatments like pirfenidone and nintedanib, emphasizing their role in slowing disease progression. It also touches on emerging therapies and their potential impact on managing advanced IPF, which is crucial for patients considering lung transplantation as a definitive treatment option [1].

Lung transplantation offers the best survival benefit for patients with advanced interstitial lung disease (ILD), including pulmonary fibrosis, who face chronic respiratory failure. This update reviews the current landscape of lung transplantation for ILD, highlighting patient selection criteria, pre-transplant optimization strategies, and post-transplant outcomes. It also addresses challenges and advancements in improving long-term graft survival [2].

Managing chronic respiratory failure in advanced pulmonary fibrosis requires a comprehensive supportive care approach. This article details essential strategies for symptomatic relief, focusing on oxygen therapy, cough management, and strategies for dyspnea. It underscores the importance of a multidisciplinary team to improve quality of life and prepare patients, where appropriate, for potential lung transplantation [3]. Palliative care is an integral component of managing idiopathic pulmonary fibrosis, especially as patients progress to chronic respiratory failure. This review emphasizes the benefits of early integration of palliative care to address symptoms, psychosocial distress, and end-of-life planning. It highlights how these services can complement disease-modifying therapies and transplant evaluations, ensuring patient-centered care throughout the illness trajectory [4].

Identifying reliable predictors for lung transplant candidacy and post-transplant survival in patients with interstitial lung disease (ILD) is crucial. This study explores various factors, including physiological parameters, functional status, and comorbidities, that influence decisions regarding waitlist placement and ultimate outcomes. Understanding these predictors helps optimize patient selection and improve resource allocation for those suffering from chronic respiratory failure awaiting transplantation [5].

Extracorporeal membrane oxygenation (ECMO) has become a vital bridge to lung transplantation for patients with end-stage interstitial lung disease (ILD) experiencing acute respiratory decompensation or severe chronic respiratory failure. This review examines the appropriate indications, management strategies, and outcomes of using ECMO in this challenging patient population. It highlights the potential for ECMO to stabilize critically ill patients, allowing them to remain viable candidates for transplantation [6].

Frailty significantly impacts outcomes following lung transplantation for interstitial lung disease (ILD). This research investigates the prevalence and prognostic implications of frailty in pre-transplant ILD patients, including those with chronic respiratory failure. It reveals that frailty is associated with increased post-transplant complications and reduced survival, underscoring the importance of comprehensive pre-operative assessment and potential interventions to optimize patient fitness for surgery [7].

Antifibrotic therapies like pirfenidone and nintedanib have revolutionized the management of progressive fibrosing interstitial lung diseases (PF-ILDs), including pulmonary fibrosis, by slowing disease progression. This review discusses the current evidence for these agents across various PF-ILDs and their role in mitigating chronic respiratory failure. It also considers how these therapies might influence the timing and necessity of lung transplantation for eligible patients [8].

Pulmonary rehabilitation is a cornerstone of care for patients with interstitial lung disease (ILD) and chronic respiratory failure, serving as a critical intervention both before and after lung transplantation. This article explores the established benefits of pulmonary rehabilitation programs, including improved exercise capacity, reduced dyspnea, and enhanced quality of life. It also addresses the unique challenges in ILD patients and highlights emerging strategies to optimize rehabilitation outcomes [9].

Donor lung selection is a critical determinant of successful outcomes in lung transplantation, particularly for recipients with end-stage interstitial lung disease (ILD) and chronic respiratory failure. This review discusses the principles and challenges of donor lung assessment, focusing on criteria that ensure optimal graft function while expanding the donor pool. It emphasizes the need for care-

***Correspondence to:** Carlos Mendez, Department of Pulmonary Diseases, University of Barcelona, Spain. E-mail: carlos.mendez@medpulmonology.es

Received: 01-May-2025, Manuscript No. AARRP-25-193; **Editor assigned:** 05-May-2025, Pre QC No. AARRP-25-193 *(PQ)*; **Reviewed:** 23-May-2025, QC No. AARRP-25-193; **Revised:** 03-Jun-2025, Manuscript No. AARRP-25-193 *(R)*; **Published:** 12-Jun-2025, DOI: 10.35841/aarrp-6.3.193

Citation: Mendez C. Advanced pulmonary fibrosis: Integrated management strategies. Res Rep Pulomonol. 2025;06(03):193.

ful balancing between recipient needs and donor organ quality to maximize post-transplant survival [10].

Conclusion

Idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (PF-ILDs) are severe conditions that culminate in chronic respiratory failure. Current anti-fibrotic treatments, notably pirfenidone and nintedanib, are instrumental in slowing disease progression and are discussed in terms of their effectiveness across various PF-ILDs. For individuals with advanced disease, lung transplantation offers the most significant survival benefit. The process involves meticulous patient selection, detailed pre-transplant optimization, and an understanding of factors influencing post-transplant outcomes, including the impact of frailty. Supportive care is a cornerstone of management, providing symptomatic relief through oxygen therapy, cough control, and dyspnea management, often delivered by a multidisciplinary team. Early integration of palliative care is also vital, addressing symptoms, psychosocial distress, and aiding in end-of-life planning, thereby complementing disease-modifying therapies and transplant evaluations. Additionally, extracorporeal membrane oxygenation (ECMO) has emerged as a crucial bridge to transplantation for critically ill patients experiencing acute respiratory decompensation. Pulmonary rehabilitation programs are essential both before and after transplantation, improving exercise capacity and quality of life. Furthermore, understanding predictors for lung transplant candidacy and survival, along with careful donor lung selection, are critical determinants for successful long-term outcomes in patients awaiting or undergoing transplantation. These integrated strategies highlight a comprehensive approach to managing advanced pulmonary fibrosis.

References

1. Michael JB, Imre N, Jonathan KE. Idiopathic Pulmonary Fibrosis: *An Update on Current and Future Treatments. Respiration.* 2021;100:975-988.
2. Enver NY, Hilary JG, Hilary MD. Lung Transplantation for Interstitial Lung Disease: *An Update. Curr Opin Pulm Med.* 2023;29:123-130.
3. Jonathan HK, Bridget FC, *Paul JW. Supportive Care in Advanced Pulmonary Fibrosis. Am J Respir Crit Care Med.* 2020;202:162-171.
4. Maryam RA, Laura BG, *Nicole G. Integrating Palliative Care in the Management of Idiopathic Pulmonary Fibrosis. J Palliat Med.* 2021;24:898-904.
5. Lauren SE, Jonathan KE, *Jason GZ. Predictors of Lung Transplant Candidacy and Survival in Patients with Interstitial Lung Disease. J Heart Lung Transplant.* 2022;41:981-989.
6. Michael RS, Matthew EB, *Pablo GS. Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation in Interstitial Lung Disease. Semin Respir Crit Care Med.* 2021;42:331-344.
7. Carli JK, Stephanie PC, *Christine HW. Frailty and Its Impact on Outcomes After Lung Transplantation for Interstitial Lung Disease. Transplantation.* 2023;107:1687-1695.
8. Kevin FC, Sonye KD, *Kevin JG. Antifibrotic Therapies for Progressive Fibrosing Interstitial Lung Diseases. Am J Respir Crit Care Med.* 2021;203:165-176.
9. Sara JW, Anne LH, Anne EH. Pulmonary Rehabilitation in Interstitial Lung Disease: Benefits, Challenges, and *Emerging Strategies. Respiration.* 2020;99:195-207.
10. John PH, Ramsey RH, *Daniel FD. Donor Lung Selection for Recipients with Interstitial Lung Disease. Semin Respir Crit Care Med.* 2022;43:880-890.

Citation: *Mendez C. Advanced pulmonary fibrosis: Integrated management strategies. Res Rep Pulomonol. 2025;06(03):193.*